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Abstract
Background: Patients with phenylketonuria (PKU) have to follow a lifelong phenylalanine restricted diet. This type of diet
markedly reduces the intake of saturated and unsaturated fatty acids especially long chain polyunsaturated fatty acids (LC-
PUFA). Long-chain saturated fatty acids are substrates of mitochondrial fatty acid oxidation for acetyl-CoA production. LC-
PUFA are discussed to affect inflammatory and haemostaseological processes in health and disease. The influence of the
long term PKU diet on fatty acid metabolism with a special focus on platelet eicosanoid metabolism has been investigated
in the study presented here.
Methodology/Principal Findings: 12 children with PKU under good metabolic control and 8 healthy controls were
included. Activated fatty acids (acylcarnitines C6–C18) in dried blood and the cholesterol metabolism in serum were
analyzed by liquid chromatographic tandem mass spectrometry (LC-MS/MS). Fatty acid composition of plasma
glycerophospholipids was determined by gas chromatography. LC-PUFA metabolites were analyzed in supernatants by
LC-MS/MS before and after platelet activation and aggregation using a standardized protocol. Patients with PKU had
significantly lower free carnitine and lower activated fatty acids in dried blood compared to controls. Phytosterols as marker
of cholesterol (re-) absorption were not influenced by the dietary fatty acid restriction. Fatty acid composition in
glycerophospholipids was comparable to that of healthy controls. However, patients with PKU showed significantly
increased concentrations of y-linolenic acid (C18:3n-6) a precursor of arachidonic acid. In the PKU patients significantly
higher platelet counts were observed. After activation with collagen platelet aggregation and thromboxane B2 and
thromboxane B3 release did not differ from that of healthy controls.
Conclusion/Significance: Long-term dietary fatty acid restriction influenced the intermediates of mitochondrial beta-
oxidation. No functional influence on unsaturated fatty acid metabolism and platelet aggregation in patients with PKU was
detected.
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Introduction
Phenylketonuria (PKU; OMIM 261600) is one of the most
common inborn metabolic diseases, approximately affecting one in
8000 newborns in Western Europe [1]. It is caused by deficient
activity of phenylalanine hydroxylase. Children with untreated
PKU suffer from severe physical and mental disability. Postnatal
diagnosis by newborn screening, early treatment with a lifelong
protein restricted diet and substitution of a phenylalanine free
amino acid formula result in a normal cognitive development [2].
Since protein-rich foods such as meat, milk products, eggs, and fish
are the predominant nutritional sources of animal fat, especially of
saturated fatty acids and long chain polyunsaturated fatty acids
(LC-PUFA), patients with PKU have a low dietary LC-PUFA
intake [3,4]. Reduced LC-PUFA concentrations in plasma and
erythrocytes have been found previously [4–7]. LC-PUFA, as
arachidonic acid (AA; 20:4n-6), docosahexaenoic acid (DHA;
22:6n-3) and eicosapentaenoic acid (EPA; 20:5n-3), are discussed
to affect inflammatory and haemostaseological processes in health
and disease [8–11]. AA, the precursor of eicosanoids, plays a
central role in proinflammatory response and haemostasis [8–10].
There is some evidence that the reduced LC-PUFA intake may
influence hemostaseological processes in PKU-patients. Decreased
concentrations of AA and its metabolite, thromboxane B2 (TXB2),
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have been found in serum [5]. In addition, the low nutritional
intake of saturated fatty acids seems to influence the concentra-
tions of intermediates (acylcarnitines) of mitochondrial beta-
oxidation of fatty acids. Patients with PKU showed a lower
concentration of free carnitine (C0) [12–15] and lower concen-
trations of the activated fatty acids (acylcarnitines) octanoylcarn-
tine (C8) and decanoylcarnitine (C10) in dried whole blood
compared to controls [15]. Furthermore, cholesterol concentra-
tions in plasma are described to be lower in patients with PKU
under good metabolic control [16–18].
We studied the metabolic pathways of saturated and unsatu-
rated fatty acids in patients with PKU and in controls, because
these pathways are suspected, to be influenced by the long-term
strict PKU diet. The aim was to get an overview of long term fatty
acid metabolome in children with PKU under strict diet and to
investigate for the first time the possible functional influences on
homeostasis using a standardized non-invasive cell-model.
Materials and Methods
Participants
Patients with diagnosed classical PKU were eligible for inclusion
if they were under good metabolic control; i.e. a documented
average phenylalanine concentration in dried blood spots was
below 360 mmol/L for patients ,10 years, below 900 mmol/l for
patients .10 years, determined at least monthly over the previous
six months. Patients with PKU followed their usual treatment
consisting of protein-restricted diet and supplementation of a
phenylalanine free amino acid formula containing also vitamins
and trace elements. Prior study entry, a diet record over three days
was performed.
Healthy controls were recruited before elective surgery (n = 4,
remove of orthopedic material) or before endocrinological testing
(n = 4, arginine test, only patients with normal test results were
included) and if they followed an omnivore Western diet. No
patient or volunteer received additional medication; especially no
cyclooxygenase inhibitors during the last 14 days prior study entry,
or over the counter nutritional supplements. Study samples were
collected while blood withdrawal for diagnostic reasons after
fasting for 4 to 6 hours.
For standardization of platelet activation experiments, 10
healthy adult volunteers (age 23–37 years, 5 females, 5 males)
were included after informed consent. All of them were on a
omnivore Western diet, without medication, especially no
cyclooxygenase inhibitors during the last 14 days prior blood
withdrawal.
Blood (10 ml) was drawn without occluding the vein from each
participant using multifly needle sets and polypropylene monov-
ettes with and without anticoagulants (Ethylenediaminetetraacetic
acid (EDTA), citrate and lithium-heparinate) obtained from
Sarstedt (Nu¨mbrecht, Germany). EDTA whole blood was dropped
on filter paper (grade 903; GE Health Care, Germany).
Procedures and Investigations
Baseline-parameters - clinical chemistry and routine
analysis. Blood count parameters were measured on the
Sysmex XE 2100 (Norderstedt, Germany). Coagulation parame-
ters (activated partial thromboplastin time (aPTT), prothrombin
time, fibrinogen, and antithrombin III (AT III) were measured on
the BCS System (Siemens, Munich, Germany). Alanine amino-
transferase, aspartate aminotransferase, gamma-glutamyl transfer-
ase, triglycerides, cholesterol, free fatty acids, creatinine, albumin,
serum proteins, c-reactive protein, sodium, potassium, and
calcium, folic acid, vitamin B12, and ferritin in serum were
measured on the Modular Analytics system from Roche (Mann-
heim, Germany). Amino acids in plasma were analyzed by ion
exchange chromatography (IEC) and ninhydrine derivatisation.
Analysis of acylcarnitines in dried blood. Acylcarnitines
in dried blood spots were measured as formerly described by liquid
chromatography/tandem mass spectrometry (LC-MS/MS) [19].
Briefly, 3.0 mm diameter punches (containing approx. 3 mL) of the
dropped-on filter paper were placed into 96-well polypropylene
micro titer plates and extracted with 100 mL of a methanol
solution, containing isotope labelled amino acid and acylcarnitine
internal standards (NSK-A, NSK-B, Cambridge Isotope Labora-
tories, Andover, USA), for 30 min by gentle shaking at room
temperature. After evaporation at 70uC for 40 min, 60 mL of 3n
butanolic-HCL was added for derivatisation at 65uC. After a
second evaporation step the samples were reconstituted with
150 mL of the mobile phase (1/1 v/v isopropanol/water) and
analysed by flow injection analysis (FIA)-MS/MS using a API
2000 triple quadrupole mass spectrometer (AB SCIEX, Darm-
stadt, Germany).
Analysis of sterols in serum. Serum concentrations of
brassicasterol, campesterol, stigmasterol, beta-sitosterol, cholester-
ol, lanosterol and desmosterol were measured by our formerly
described LC-MS/MS method using a API 3000 triple quadru-
pole mass spectrometer with photospray ionization (AB SCIEX,
Darmstadt, Germany) [20]. 10 mL of human serum were diluted
with 490 mL of 50/50 v/v methanol/acetonitrile. After centrifu-
gation, free and esterified beta-sitosterol, campesterol, and
brassicasterol were simultaneously analyzed by LC-MS/MS.
Fatty acid composition of plasma
glycerophospholipids. The analysis of plasma glyceropho-
spholipid composition was performed by a sensitive and precise
high-throughput method recently described [21]. In brief, 100 ml
of serum, 100 ml of internal standard (1,2-dipentadecanoyl-sn-
glycero-3-phosphocholine dissolved in methanol) and 0.6 ml
methanol (precooled to 5uC) were combined in glass tubes and
shaken for 30 s. Samples were centrifuged and the supernatant
was transferred into another glass tube. Sodium methoxide
solution (25 ml) was added, tubes were shaken, and synthesis of
methyl esters proceeded at room temperature. The reaction was
stopped after 3 minutes by adding 75 ml methanolic HCl. Fatty
acid methyl ester (FAME) were extracted twice by adding 300 ml
hexane at a time. Extracts were combined and dried under
nitrogen flow at room temperature and taken up in 50 ml hexane
(containing 2 g/l BHT) for gas chromatographic (GC) analysis.
Individual FAMEs were quantified by GC with flame ionization.
Eicosanoid analysis in plasma and
supernatants. Eicosanoids in EDTA plasma and supernatants
after activation of platelet rich citrate-plasma were analyzed by
LC-MS/MS [22]. Solid phase extraction (SPE) was used for
extraction and concentration of the eicosanoids [23]. 150 ml of the
platelet supernatants or EDTA plasma were spiked with 50 ml 1/1
v/v methanol/water containing 0.2 mg/ml of arachidonic acid-d8
(AA-d8) and 0.02 mg/ml of prostaglandin F2a-d4 (PGF2a-d4),
prostaglandin E2-d4 (PGE2-d4), leukotriene B4-d4 (LTB4-d4), and
5-S-hydroxyeicosatetraenoic acid-d8 (5-HETE-d8), thromboxane
B2-d4 (TxB2-d4), eicosapentaenoic acid-d5 (EPA-d5), and doc-
osahexaenoic acid-d5 (DHA-d5). The samples were extracted
using Strata X SPE columns (Phenomenex, Aschaffenburg,
Germany). Samples were dried under nitrogen and stored at
280uC until analysis. After elution 10 ml of each aliquot were
injected into the LC-MS/MS system. Chromatographic separa-
tion was performed based on the protocols by Deems et al [23].
A triple quadrupole mass spectrometer (API 5500 QTrap, SCIEX
Toronto, Canada) using electrospray ionization (ESI) was used in
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negative ion mode. Analytes were quantified in multiple reaction
monitoring transitions (MRMs) using the corresponding labeled
internal standards [22]. Table S1 shows the analyzed metabolites.
Platelet function analysis. In a first step a standardized
protocol for reproducible platelet activation with collagen and
analysis of subsequent eicosanoid release was developed.
For standardization TXB2 release after platelet activation was
used. The measured metabolite TXB2 is a stable, biologically inert
metabolite formed from the non-enzymatic hydrolysis of TXA2
[24]. The latter has a half-life of approximately 30 seconds [24].
TXB2 in plasma and urine reflects platelet TXA2 synthesis [25].
Thromboxane B3 (TXB3) is the equivalent metabolite metabolized
competitively by the same enzymes from omega-3 LC-PUFA (i.e.
EPA) [8].
Platelet-rich plasma (150 Gpt/l 615) of freshly drawn citrate-
blood from five healthy adult volunteers was activated with
collagen. After 10 minutes of platelet activation (compared to 1
and 5 minutes) with collagen a plateau of TXB2 release was found.
Variability for TXB2 release after platelet activation with collagen
was tested. Intra-assay variability, activation three times consec-
utively, was #6.2%. Between-day variability, at three consecutive
days, blood withdrawal at noon, was #8.7%. Circadian variability
was #14.8%. Therefore, platelet activation from five healthy
subjects was performed after blood withdrawal once in the
morning, at noon and in the afternoon at three consecutive days.
Interindividual variability of TXB2 release after platelet activation
with collagen was 15.6%.
From this data the following standardized protocol was
established: 225 ml platelet-rich plasma (150 Gpt/l 615 Gpt/l)
from freshly drawn citrate-blood was transferred to three micro
glass silicon tubes with magnetic stirrers on Platelet Aggregation
Profiler 4 (PAP 4, mo¨lab, Langenfeld, Germany). In two samples
platelet activation was performed with bovine collagen (25 ml,
1.9 g/l) for 10 minutes, registered by the PAP 4 (mo¨lab,
Langenfeld, Germany). The third sample remained inactivated
for 10 minutes. Afterwards, stirrers were removed, plasma
transferred to 0.5 ml tubes (Eppendorf, Hamburg, Germany)
and centrifuged at 5260 g for 10 minutes (20uC) to remove
platelets and cell detritus. The supernatants were stored at 280uC
under nitrogen to avoid oxygen-induced radical formation until
analysis.
Ethics
The study protocol was approved by the local ethics committee
of the Medical Faculty of the University of Leipzig (Leipzig,
Germany; registration number 021-09-180808). The trial was
performed in accordance with the Declaration of Helsinki/
Somerset West and followed ICH-GCP guidelines. Informed
written consent was obtained from all patients and/or parents.
Statistical Methods
All statistical analyses were performed using PASW statistic 18
(Chicago, IL, USA). For descriptive reasons we displayed the
median and minimum/maximum of all data. Wilcoxon-test, for
paired samples, or Mann-Whitney-U-test, for independent sam-
ples, was used. A probability value of p,0.05 was considered
significant.
For initial analysis the study population was divided in groups
regarding age (patients ,10 years, patients .=10 years) or
regarding diet (phenylalanine consumption ,300 mg/day, 300–
400 mg/day, .400 mg/day). This did not influence the results.
Therefore, final analysis was performed using the entire sample.
Results
Participants
12 (6 females, 6 males) early treated children and adolescents
with classical PKU aged 5–14 years and 8 healthy controls (5
females, 3 males) aged 5–17 years were included in the study.
Age, height, weight, body mass index (BMI) and Tanner stages
did not differ significantly between the two groups (Table S2).
Diet Records and Basic Laboratory Parameters
The results of the diet records of patients with PKU were
compared to the regular daily allowance, recommended for the
German speaking countries [26] as shown in table 1. The
overall energy intake was just below the recommended amount.
None of the 12 PKU-patients had signs of over- or undernu-
trition with a median BMI SDS of 0.6 (21.24–1.51; Table S2).
Nevertheless, the patients reached only about 75% of the
recommended fat intake under the strict PKU diet. Median fat
intake from vegetable sources was 56.9% (45.1–91.8%; pre-
dominant vegetable oil) and from animal sources was 42.7%
(8.2–55.1%, predominant butter). Although fat intake was under
the recommended amount, the precursors of AA and DHA,
linoleic acid and alpha-linolenic acid, respectively, were
consumed as recommended (Table 1).
Carbohydrate intake was slightly below the recommended
amount and the intake of protein was sufficient under substitution
of amino acid formula [26] (Table 1).
Basic liver and kidney parameters, electrolytes, lipids, infection
parameters, and coagulation parameters were within the normal
range in both groups without significant differences. In PKU
patients, essential amino acid concentrations in plasma were
within the normal range except from the elevated phenylalanine
concentrations (Table S2).
Patients with PKU showed a significant higher median platelet
count (329 Gpt/l, range 257–435 Gpt/l) compared to controls
(271.5 Gpt/l, range 197–330 Gpt/l) (p,0.05). Platelet volume in
patients with PKU was 10.2 fL (7.8–11.8 fL) compared to controls
Table 1. Analysis of three-day diet record of patients with
phenylketonuria (PKU).
Patients with PKU
(n=12)
median (range)
Energy intake [kcal/day] 1678.0 (919–2075)
% DACH RDA 98 (66–131)
Carbohydrates [g/day] 232.6 (148.4–367.5)
% DACH RDA 93 (69–127)
Proteine [g/day] 41.1 (22.5–78.3)
% DACH RDA 197 (132–321)
Fat [g/day] 47.3 (18–65)
% DACH RDA 75 (28–125)
Phenylalanine [mg/day] 338 (254–690)
Linoleic acid [mg/day] 4536 (876–10866)
% DACH RDA 110 (67–240)
alpha-linolenic acid [mg/day] 805 (219–1461)
% DACH RDA 96 (22–182)
% DACH RDA: percentage of regular daily allowance, recommended for the
German speaking countries [26].
doi:10.1371/journal.pone.0043021.t001
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9.6 fL (7.1–10.4 fL) (p = 0.063) (Figure 1, Table S2). Plasma
concentrations of folic acid (p,0.01), vitamin B12 (p,0.01), and
ferritin (p,0.05) in patients with PKU were significantly higher
than in controls (Table S2).
Investigations of Saturated Fatty Acid Metabolism,
Mitochondrial Beta-oxidation, Cholesterol Adsorption
and Synthesis
Patients with PKU had significantly lower concentrations of free
carnitine (C0) (p,0.01), total acylcarnitines (p,0.001) and of
activated fatty acids of the different chain-lengths (p,0.001: C2,
C3, C18, C18OH, C18:1), (p,0.01: C4–0H, C5, C8), (p,0.05:
C6, C10:1, C14:1, C16:1, C18:2) compared to the healthy
controls (Figure 2, Table S3).
Serum concentrations of cholesterol absorption markers brassi-
casterol, campesterol, stigmasterol, beta-sitosterol, and lanosterol
as marker for cholesterol synthesis did not differ significantly
between both groups. Also the cholesterol concentration and the
relative non-cholesterol concentrations showed no significant
differences (Table S3).
Investigation of Unsaturated Fatty Acid Metabolism
Patients with PKU showed significant higher concentrations
of y-linolenic acid (C18:3n-6) (2.1 mg/l, range 1.0–5.1 mg/l
versus 1.1 mg/l, range 0.6–2.4 mg/l; p,0.01) and a trend to
higher concentrations of di-homo-y-linolenic acid (C20:3n-6)
(43.3 mg/l, range 33.0–60.0 mg/l versus 36.2 mg/l, range
30.0–52.8 mg/l; p = 0.069) in plasma glycerophospholipids
(Table S3, Figure 3). Both are precursors in endogenous AA
synthesis. For other fatty acids of plasma glycerophospholipids
no differences between patients with PKU and controls were
found (Table S3).
There was no difference for TXB2 (derived from AA) plasma
concentrations in the study groups. However, TXB3 (derived from
EPA) plasma concentrations were significantly lower in patients
with PKU (0.01 ng/ml, range 0.00–0.12 ng/ml) compared to
controls (0.10 ng/ml, range 0.03–0.25 ng/ml; p,0.005; Table
S3).
Functional Investigations of Platelet Activation Induced
Eicosanoid Release
Platelet activation with collagen for 10 minutes induced a
significant release of AA, TXB2, TXB3, prostaglandin E2
(PGE2), prostaglandin D2 (PGD2), 11-S-hydroxyeicosatetraenoic
acid (11-HETE), and 12-S-hydroxyeicosatetraenoic acid (12-
HETE) in patients with PKU and controls (Table 2). The
concentrations of TXB2, TXB3, PGE2, PGD2, 11-HETE, and
12-HETE after platelet activation with/without collagen did not
differ significantly between the two groups. To assure repro-
ducibility of analysis of eicosanoid release after platelet
activation we validated a standardized protocol for the
activation experiments.
Figure 1. Platelet count and platelet volume. Data of patients with phenylketonuria (PKU) (n = 12) and healthy controls (n = 8). A platelet count
(* p,0.05) and B platelet volume. The stripe marks the median.
doi:10.1371/journal.pone.0043021.g001
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Discussion
PKU-patients have to undergo a livelong phenylalanine
restricted diet beginning in the first weeks of life, which is
associated with a long-term restriction of saturated and non-
saturated fatty acids compared to a regular western diet [5,7,13–
15,17,18,27].
As may be expected, the investigated PKU patients had only
75% (median 47,3 g per day) of the age related recommended fat
intake [26]. Similar results have been found previously [18,27,28].
Moreover, an inverse relation of animal to vegetable fat was
observed in our PKU group (42.7% animal fat/56.9% vegetable
fat). In contrast healthy German children 6–11 years/12–17 years
consume 62.5 g/100.5 g fat per day, including 65.7% animal fat
and 34.3% vegetable fat [29]. However, the intake of the essential
fatty acids linoleic acid and alpha-linolenic acid, precursors for
endogenous AA and DHA synthesis, was in the recommended
range [26].
The influence of the restricted intake of saturated fatty acids
with the PKU diet was found to be evident in both, the
metabolism of C0 and the intermediates of mitochondrial ß-
oxidation [15]. We observed significantly lower C0 and acylcarni-
tine concentrations in dried whole blood of PKU patients,
although free fatty acids in serum were comparable between
PKU patients and controls. Lower C0 concentrations in patients
with PKU on a strict diet have been described previously as
possible consequence of the low nutritional carnitine intake [14] or
the reduced endogenous synthesis due to the lower plasma
concentrations of the essential substrates methionine and lysine
[15]. Additionally phenylacetic acid, a pathological metabolite
found in serum and urine of PKU-patients, was found to be
capable of inhibiting the endogenous carnitine synthesis [30].
However concentrations of C0 are not as low as in other inborn
Figure 2. Free carnitine and acylcarnitines. Data of patients with phenylketonuria (PKU) (n = 12) and healthy controls (n = 8); measured by liquid
chromatography/tandem mass spectrometry (LC-MS/MS). A Free carnitine (C0) in dried blood (**p,0.01). B Total acylcarnitines in dried blood
(***p,0.001). C Octadecanoylcarnitine (C18) in dried blood (***p,0.001). D Octadecenoylcarnitine (C18:1) in dried blood (***p,0.001).
doi:10.1371/journal.pone.0043021.g002
Figure 3. Arachidonic acid and y-linolenic acid concentrations in plasma glycerophospholipids. Data of patients with phenylketonuria
(PKU) (n = 12) and healthy controls (n = 8). A Arachidonic acid in plasma glycerophospholipids. B y-linolenic acid in plasma gylcerophospholipis (**
p,0.01).
doi:10.1371/journal.pone.0043021.g003
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metabolic diseased like carnitine transporter defects known to
show clinical symptoms, as (cardio-) myopathy. However, up to
now, there is no data of long-term follow up in adult PKU patients
available. Interestingly, carnitine substitution in amino acid
formula appears not to affect carnitine and acylcarnitine status
in patients with PKU [15]. We could confirm these findings, as the
carnitine substitution (mean 27 mg/d, 10–48 mg/day per person)
of four PKU patients of our study group did not affect their
carnitine and acylcarnitine status (data not shown).
Next to reduced C8 und C10 concentrations in dried whole
blood in PKU patients, as already being described in a previous
study [15], also decreased concentrations of the C16- and C18-
fatty acids as substrates of mitochondrial beta-oxidation as well as
their intermediates (C14–C6) were found. The reduced concen-
trations of C18 acylcarnitine and of the intermediates may reflect
the reduced fat intake, a diminished mobilization of fatty acids
from fat tissue, and a lower energy production by ß-oxidation in
patients with PKU. Furthermore: as result acetyl-CoA (measured
as acetylcarnitine C2), the central metabolite in the energy
metabolism and the link between carbohydrate, amino acid, and
fatty acid metabolism, was significant lower in PKU patients
compared to controls. However, no association to lower
phospholipids, free fatty acids, ketone bodies, or cholesterol
concentrations could be revealed.
Because of the lower total fat intake and the higher amount
of nutritional fat intake as vegetable oil in the PKU diet [28],
we initially suspected that serum cholesterol might be lower and
the cholesterol synthesis might be higher in PKU patients
compared to controls. In our study cohort, serum cholesterol
concentrations did not differ between patients with PKU and
healthy controls. These findings are in contrast to previous
studies revealing lower serum cholesterol concentrations in
patients with PKU [16,17,27], especially while under good
metabolic control [18], and also compared to patients with a
protein-restricted diet due to other inborn errors of amino acid
metabolism [27]. Other studies showed a possible inhibition of
cholesterol synthesis in vitro [31] and in animal models of PKU
[32]. Colome´ et al. [27] detected an inverse correlation of
phenylalanine and cholesterol concentrations in serum and
hypothesized high plasma phenylalanine concentrations to
inhibit cholesterol synthesis. We could not confirm these results,
because the marker for cholesterol synthesis lanosterol and the
lanosterol/cholesterol ratio did not differ significantly between
the two groups, who were comparable in BMI and Tanner
stages.
LC-PUFA play an important role in neuronal development and
cognitive function [33–37]. The imbalanced PKU diet with nearly
absence of animal proteins and markedly reduced fatty acids of
animal sources is known to result in lower plasma and cell
membrane concentrations of LC-PUFA [4–7]. We could not
confirm reduced LC-PUFA levels in the PKU study group. AA,
EPA and DHA in plasma glycerophospholipids, a good biomarker
for dietary fatty acid intake and body status [21], were comparable
in both study groups and adequate regarding reference values of
serum glycerophospholipids in children [38,39]. This may be
caused by a higher endogeneous LC-PUFA synthesis in our
patients supported by the fact that we found higher concentrations
of AA precursors y-linolenic acid (C18:3n-6) and di-homo-y-
linolenic acid (C20:3n-6) in plasma glycerophospholipids. In
addition, intake of the essential fatty acids linoleic acid and a-
linolenic acid was as recommended. Former studies reported that
even an enhanced dietary intake of a-linolenic acids was not
sufficient to increase DHA-phosholipid concentrations in infants
[40–42].
Reactive thrombocytosis was described to be associated with
metabolic diseases in children [43,44]. The PKU patients studied
here had higher platelet count and a trend to higher platelet
volume compared to controls, but showed no other signs leading
to reactive thrombocytosis (e.g. no infection, iron, cobalamin, and
folic acid deficiency). These results were reproduced in a bigger
PKU cohort of our outpatient clinic (n = 49, data not shown).
Plasma AA and TXB2 concentrations did not differ between
both groups. In contrast, Agostoni and colleagues found reduced
serum TXB2 and AA concentrations [5]. However, plasma
concentrations of TXB3, metabolite of EPA, were significantly
lower in PKU patients compared to the control group. This may
indicate a reduced omega-3 LC-PUFA metabolism in PKU
patients, although, the amount of EPA and DHA in plasma
glycerophospholipids was adequate regarding reference values
[38,39].
Based on the fact that we found more and larger platelets which
are known to contain more granules producing higher amounts of
vasocative and prothombotic factors [45–47] and the hypothesis
that the dietary restriction of fatty acids, especially LC-PUFA,
affects the platelet function, we established a well standardized
protocol for platelet activation and eicosanoid release. Collagen
Table 2. Eicosanoid concentrations in supernatants after 10 minutes of activation of platelet rich plasma (225 ml; 150615 Gpt/l)
with/without collagen in patients with phenylketonuria (PKU) and healty controls.
PKU (n=11)
median (Range)
Controls (n=8)
median (Range)
Without collagen With collagen Without collagen With collagen
AA [ng/ml] 1470 (948–2470) 3720 (2880–5520) 1520 (1070–2610) 3830 (3400–5130)
TXB2 [ng/ml] 6.0 (2.7–21.8) 390 (252–502) 3.9 (2.2–10.2) 351 (262–534)
TXB3 [ng/ml] 0.17 (0–0.46) 2.56 (0.77–4.28) 0.1 (0–0.4) 2.59 (1.57–3.59)
PGE2 [ng/ml] 0.24 (0.1–2.65) 11.5 (6.0–15.5) 0.20 (0–0.33) 11.2 (5.9–17.6)
PGD2 [ng/ml] 0.08 (0.02–0.24) 1.56 (0.51–4.38) 0.03. (0.01–0.08) 1.0 (0.51–1.97)
11-HETE [ng/ml] 1.64 (0.84–2.36) 44.4 (26.2–58) 1.45 (0.96–3.14) 38.3 (29.6–366)
12-HETE [ng/ml] 9.03 (4.18–15.6) 299 (120–425) 7.37 (3.71–11.5) 279 (209–411)
AA= arachidonic acid, TXB2, = thromboxane B2, TXB3 = thromboxane B3, PGE2 =prostaglandin E2, PGD2= prostaglandin D2, 11-HETE = 11-S-hydroxyeicosatetraenoic acid,
12-HETE = and 12-S-hydroxyeicosatetraenoic acid.
doi:10.1371/journal.pone.0043021.t002
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was chosen for activation of the cyclooxygenase and lipoxygenase
pathway. No differences between the two groups concerning
aggregation and platelet eicosanoid release were found, neither
analysing TXB2, nor TXB3. The same was true for total
eicosanoid concentrations with or without activation and for the
percental increase of eicosanoid concentrations after activation.
This is an important finding, as it shows that although PKU
patients follow a strict diet, which influences LC-PUFA status,
cellular eicosanoid metabolism seems not to be affected as it were
shown for platelet aggregation. Nevertheless, we found more than
15% interindividual variability of TBX2 release. The number of
study subjects in each group maybe therefore too small to answer
this question definitely.
In conclusion, fat is an essential part of nutrition. It affects many
different metabolic pathways. We applied a LC-MS/MS approach
to some of these pathways to analyze the influence of the moderate
long-term fatty acid restriction in PKU patients on the
metabolome of saturated and unsaturated fatty acids and found
for the first time the diet to influence the complete mitochondrial
ß-oxidation pathway and energy metabolism, but not cholesterol
metabolism. In our newly established cellular experiment, patients
with PKU were found to have more large platelets, but the
aggregation and platelet eicosanoid release was not different from
healthy controls. To assess the value of these findings for the
possible resulting comorbidities, the long-term outcome of PKU
patients, and potential therapeutic approaches further studies with
bigger cohorts and older PKU patients should be investigated.
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